tiprankstipranks
Ardelyx (MX:ARDX)
:ARDX
Mexico Market

Ardelyx (ARDX) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

ARDX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Ardelyx
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ARDX Stock 12 Month Forecast

Average Price Target

$230.26
▲(283.76% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Ardelyx in the last 3 months. The average price target is $230.26 with a high forecast of $304.19 and a low forecast of $152.10. The average price target represents a 283.76% change from the last price of $60.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","182":"$182","305":"$305","120.5":"$120.5","243.5":"$243.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":304.19279064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$304.19</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230.257042915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$230.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":152.09639532,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$152.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,120.5,182,243.5,305],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,78.78406081846154,97.56812163692308,116.35218245538461,135.13624327384616,153.92030409230767,172.70436491076921,191.48842572923076,210.2724865476923,229.05654736615384,247.84060818461538,266.6246690030769,285.40872982153843,{"y":304.19279064,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,73.09669560884615,86.19339121769231,99.29008682653847,112.38678243538462,125.48347804423076,138.58017365307694,151.6768692619231,164.77356487076923,177.87026047961538,190.96695608846153,204.0636516973077,217.16034730615385,{"y":230.257042915,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60,67.08433810153846,74.16867620307693,81.25301430461539,88.33735240615385,95.42169050769232,102.50602860923077,109.59036671076923,116.6747048123077,123.75904291384616,130.84338101538464,137.92771911692307,145.01205721846154,{"y":152.09639532,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.2,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.2,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.2,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.8,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.8,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.8,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.8,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$304.19Average Price Target$230.26Lowest Price Target$152.10
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush
$152.1
Buy
153.49%
Upside
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)
Piper Sandler Analyst forecast on MX:ARDX
Piper Sandler
Piper Sandler
$270.39$253.49
Buy
322.49%
Upside
Reiterated
08/17/26
Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler
Citi
$236.59$185.9
Buy
209.83%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on MX:ARDX
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$270.39
Buy
350.66%
Upside
Reiterated
08/10/26
Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)
H.C. Wainwright Analyst forecast on MX:ARDX
H.C. Wainwright
H.C. Wainwright
$304.19
Buy
406.99%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on MX:ARDX
Raymond James
Raymond James
$321.09$253.49
Buy
322.49%
Upside
Reiterated
08/07/26
Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James
TD Cowen Analyst forecast on MX:ARDX
TD Cowen
TD Cowen
$219.69$169
Buy
181.66%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Jefferies Analyst forecast on MX:ARDX
Jefferies
Jefferies
$253.49
Buy
322.49%
Upside
Reiterated
06/26/26
Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'
BTIG
$287.29
Buy
378.82%
Upside
Reiterated
02/20/26
Ardelyx (ARDX) Receives a Buy from BTIG
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wedbush
$152.1
Buy
153.49%
Upside
Reiterated
08/18/26
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NASDAQ: NRXP), DocGo (NASDAQ: DCGO) and Ardelyx (NASDAQ: ARDX)
Piper Sandler Analyst forecast on MX:ARDX
Piper Sandler
Piper Sandler
$270.39$253.49
Buy
322.49%
Upside
Reiterated
08/17/26
Ardelyx price target lowered to $15 from $16 at Piper SandlerArdelyx price target lowered to $15 from $16 at Piper Sandler
Citi
$236.59$185.9
Buy
209.83%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Ladenburg Thalmann & Co. Analyst forecast on MX:ARDX
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$270.39
Buy
350.66%
Upside
Reiterated
08/10/26
Ladenburg Thalmann & Co. Remains a Buy on Ardelyx (ARDX)
H.C. Wainwright Analyst forecast on MX:ARDX
H.C. Wainwright
H.C. Wainwright
$304.19
Buy
406.99%
Upside
Reiterated
08/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Raymond James Analyst forecast on MX:ARDX
Raymond James
Raymond James
$321.09$253.49
Buy
322.49%
Upside
Reiterated
08/07/26
Ardelyx price target lowered to $15 from $19 at Raymond JamesArdelyx price target lowered to $15 from $19 at Raymond James
TD Cowen Analyst forecast on MX:ARDX
TD Cowen
TD Cowen
$219.69$169
Buy
181.66%
Upside
Reiterated
08/06/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
Jefferies Analyst forecast on MX:ARDX
Jefferies
Jefferies
$253.49
Buy
322.49%
Upside
Reiterated
06/26/26
Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'Jefferies says Ardelyx CMS appeal loss 'shouldn't fundamentally change anything'
BTIG
$287.29
Buy
378.82%
Upside
Reiterated
02/20/26
Ardelyx (ARDX) Receives a Buy from BTIG
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
SNDXSyndax Pharmaceuticals
PTGXProtagonist Therapeutics
ONCBeOne Medicines
HITIHigh Tide
IRTCIrhythm Technologies
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ardelyx

3 Months
Success Rate
9/17 ratings generated profit
53%
Average Return
+29.77%
Copying Yigal Nochomovitz's trades and holding each position for 3 Months would result in 52.94% of your transactions generating a profit, with an average return of +29.77% per trade.
1 Year
Christopher RaymondRaymond James
Success Rate
8/17 ratings generated profit
47%
Average Return
+22.35%
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +22.35% per trade.
2 Years
Christopher RaymondRaymond James
Success Rate
7/17 ratings generated profit
41%
Average Return
+10.66%
Copying Christopher Raymond's trades and holding each position for 2 Years would result in 41.18% of your transactions generating a profit, with an average return of +10.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARDX Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
6
8
6
10
8
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
8
6
10
8
In the current month, ARDX has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ARDX average Analyst price target in the past 3 months is 230.26.
Each month's total comprises the sum of three months' worth of ratings.

ARDX Financial Forecast

ARDX Earnings Forecast

Next quarter’s earnings estimate for ARDX is -$0.24 with a range of -$1.01 to $0.42. The previous quarter’s EPS was -$1.18. ARDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.
Next quarter’s earnings estimate for ARDX is -$0.24 with a range of -$1.01 to $0.42. The previous quarter’s EPS was -$1.18. ARDX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.

ARDX Sales Forecast

Next quarter’s sales forecast for ARDX is $2.19B with a range of $2.02B to $2.27B. The previous quarter’s sales results were $2.04B. ARDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.
Next quarter’s sales forecast for ARDX is $2.19B with a range of $2.02B to $2.27B. The previous quarter’s sales results were $2.04B. ARDX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ARDX has Performed in-line its overall industry.

ARDX Stock Forecast FAQ

What is MX:ARDX’s average 12-month price target, according to analysts?
Based on analyst ratings, Ardelyx’s 12-month average price target is 230.26.
    What is MX:ARDX’s upside potential, based on the analysts’ average price target?
    Ardelyx has 283.76% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ardelyx a Buy, Sell or Hold?
          Ardelyx has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ardelyx’s share price target?
            The average share price target for Ardelyx is 230.26. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $304.19 ,and the lowest forecast is $152.10. The average share price target represents 283.76% Increase from the current price of $60.
              What do analysts say about Ardelyx?
              Ardelyx’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Ardelyx?
                To buy shares of MX:ARDX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.